Cost of Protein Expression Failure Across R&D Project Stages

Protein expression failure has different costs at discovery, lead optimization, and preclinical development. Its economic impact depends on which candidates it removes, how much investment precedes it, and which work it prevents. That makes reliable expression a choice about where to invest as well as which technique to use.

Why protein expression failure is a cost problem, not just a scientific one

A failed expression run consumes reagents and personnel time, but those direct expenses capture only part of the loss. It can also remove a viable target, distort candidate selection, or delay a program whose next experiments depend on usable protein. Treating the event as a laboratory troubleshooting problem therefore understates its effect on the program budget and the decisions that budget supports.

Independent studies put the cost of each approved drug in the hundreds of millions to billions of dollars when the full cost of failures is included. The range comes from measurement error and choices about accounting, including out-of-pocket spending versus capitalized costs and differences in which companies are sampled. Failed candidates are embedded in the cost of eventual approvals. Expression-driven attrition belongs in that accounting even when it occurs before a program produces evidence about pharmacology.

How the R&D pipeline stages create distinct failure cost profiles

Discovery, lead optimization, and preclinical development expose programs to different combinations of direct expense, timeline risk, and lost opportunity. Discovery spreads relatively inexpensive experiments across many targets, while optimization concentrates work on candidates that have already survived selection. Preclinical development concentrates resources further, adding expensive assays, regulatory-quality data requirements, and cross-functional work. The same technical failure therefore has unequal consequences. Its cost depends on the investment behind the candidate and the decision that the missing protein prevents.

A protein that cannot be produced may disappear from consideration without registering as a failed pharmacological hypothesis. At optimization, expression failure can waste the work already done to choose candidates and hold up comparisons between variants. At preclinical development, it can block studies and reset timelines by months.

Expression failure also differs from failure of the biology being studied. Insolubility, host toxicity, inclusion body formation, and host-cell stress can stop protein production without showing that a target has no pharmacological value. The platform can become the barrier to testing. Program-level accounting may record the same outcome in either case, but the scientific interpretation is different. A candidate eliminated by production constraints has not necessarily received a meaningful biological test.

Expression failure at discovery: the silent elimination of valid targets

Expression failure at discovery is costly in part because it can go unnoticed. An insoluble, inactive, or proteolytically unstable protein may be treated as a target that “didn't work,” even though the experiment never established whether the target was useful. That distinction can vanish from subsequent selection decisions. The immediate loss is a failed production attempt, but the strategic loss is a candidate removed on platform-based grounds.

A documented screen of human kinases illustrates the gap between expression and usable protein. The screen expressed the majority of the kinases in E. coli, yet nearly half of those expressed were insoluble or only partially soluble. Production alone was not sufficient for testing. Nor does insolubility in one system establish that the protein cannot be produced in another. The example shows how an expression workflow can filter the candidate pool before pharmacology has a chance to do so.

The opportunity cost is therefore asymmetric. The failed experiment may cost little, but discarding a truly valuable target can mean losing a whole downstream program before it begins. That risk is particularly acute for membrane proteins, intrinsically disordered proteins, toxic proteins, and multi-domain assemblies, which cell-based systems can handle poorly. Their production difficulty does not diminish their biological interest. Instead, it makes platform suitability part of which questions discovery can investigate.

Parallel expression screening cuts the time spent working through those limits on production. A 2025 Current Protocols paper reported a validated 96-well approach that screened 80 constructs for expression and solubility and identified candidates suitable for scale-up. Failures became visible early in the screening process. Cell-free protein synthesis, or CFPS, is well suited to this work because it can bypass cloning and transformation, run directly from PCR products, and express many open reading frames in a single day. Once a candidate survives discovery, however, the economic task shifts from making it testable to comparing its variants reliably.

Expression failure at lead optimization: compounding cost on a narrowing set of candidates

Lead optimization begins with a smaller population that already embodies discovery investment. Each failed expression attempt now interrupts work on a candidate selected for further attention. The cost per event consequently rises. Teams are comparing variants, mutations, or constructs to find the desired combination of activity, stability, and expressibility, so protein production determines how quickly those comparisons can proceed.

Throughput is the decisive economic variable at this stage. A platform that expresses and supports assays for many variants in parallel compresses the optimization cycle, while sequential construct handling stretches it. The Current Protocols multiwell-plate method demonstrated combined expression, export, and assay for identifying proteins suitable for biochemical assays and structural analyses. This connects production directly to the selection workflow.

Those comparisons lose value when reagent performance changes between runs. Lot-to-lot differences in expression yield or protein quality can shift variant rankings, causing a viable candidate to be deprioritized after a poor-performing reagent lot. The loss is both experimental and decisional. One expense comes from the failed run, while another comes from selecting against a candidate for a reason unrelated to its underlying merits. Undisclosed or incompletely characterized reagent composition makes that distinction harder to recover.

Cell-free expression addresses some of these difficulties by separating protein production from cellular viability. Toxic variants and variants that provoke cellular stress can be produced without requiring a host to tolerate their expression, and the approach avoids the cellular context of inclusion body formation. That advantage does not make every result self-explanatory. Without stable reagents and sufficient formulation information, an unsuccessful optimization run can still leave the central question unresolved. The variant may have failed, or the reagent may have failed it.

Expression failure at the preclinical stage: when the cost becomes structural

By the time expression fails at the preclinical stage, teams have already spent time and money on discovery and optimization. Protein quantity and quality requirements are also far higher than those of initial screening, with consistent milligram quantities of well-characterized protein needed for assay development, structural studies, and sometimes animal studies. Production becomes a program-level operational dependency whose failure can interrupt several kinds of work.

Batch consistency is central to that dependency. If protein production changes between batches, results may no longer be comparable across runs, and studies may need to be repeated. The need for regulatory-quality data makes that uncertainty more costly. The expense includes both the resources committed to generating the data and the replacement protein. At this stage, reliable supply is inseparable from the ability to interpret successive experiments.

Sertkaya et al. found that the nonclinical share of total R&D costs rises sharply when failures are included. Late failure threatens the return on earlier investment. The Congressional Budget Office reports that only a small fraction of drugs that enter clinical trials reaches approval, and expression-driven attrition before clinical entry means teams lose even the chance to learn from those trials.

An emerging biotech or academic lab can exhaust a program cycle’s reagent and personnel budget on a preclinical expression problem, with timeline slippage affecting funding milestones. Cost-per-gram governs whether a cell-free workflow can supply the required quantities without restricting the experiments available to the team. This concentration of risk is a reason to allocate expression infrastructure investment by stage, with reproducibility treated as part of that investment.

How reproducibility failures multiply the cost of expression failure at every stage

Reagent variability amplifies each stage’s distinct exposure by making failures difficult to diagnose. When composition is opaque, an unsuccessful run does not clearly distinguish a biological limitation from a reagent problem. The researcher may repeat the experiment, change the construct, or abandon the candidate. Each response consumes resources or opportunity. Repetition offers a chance to recover the original answer, whereas changing or discarding the candidate can leave the cause of the initial failure unresolved.

Even a reagent-lot substitution or media-vendor change can alter experimental outcomes. If composition is undisclosed, the relevant change may not be visible to the researcher, making apparent biological differences difficult to interpret. Freedman et al. estimated in 2015 that irreproducible preclinical research costs billions annually in one country, with biological reagents and reference materials representing a substantial portion. That estimate is broader than protein expression, but it identifies the same underlying risk of results that cannot be reproduced.

Lot-level QC data and documented formulations make that uncertainty more tractable. Quantitative benchmarks and information about changes between lots help researchers localize failure instead of treating every unsuccessful run as a new biological question. OpenCFPS™ offers documented formulations and lot-level QC data as a concrete example of this approach. Better documentation can reduce the work required to distinguish reagent variation from limitations of the protein or construct.

The 2025 bioRxiv preprint describing i-POPFLEX approaches the problem through defined components. It identifies the undefined composition of crude lysates as a constraint on reproducibility and systematic optimization. Defined composition makes controlled investigation more feasible. That rationale is distinct from the architecture’s reported improvement in batch-to-batch variability, which the associated work attributes to automation.

What the stage-by-stage cost structure implies for expression platform decisions

At discovery, investment should prioritize throughput and rapid identification of expression constraints. The goal is to test constructs and conditions cheaply before a production limitation silently excludes a useful target or absorbs optimization resources. Plate-based CFPS workflows fit that requirement. Their compatibility with standard laboratory automation supports parallel screening, while direct use of PCR products shortens the path to testable protein.

At lead optimization, the priority should shift toward consistency and diagnostic clarity. Variant rankings are useful only when differences reflect the candidates. Documentation therefore has direct economic value. OpenCFPS™ is designed for high-throughput variant screening in plate format, with pricing and documentation intended to support systematic, reproducible work at meaningful scale. Lot-level QC supports this use case by making failures interpretable.

At preclinical development, teams should weigh how reliable the yield is and the cost-per-gram against their need for consistent milligram quantities. A 2025 Nature Communications formulation study demonstrated gram-per-liter cell-free production at a cost per gram competitive with cell-based systems. OpenCFPS™ offers a milligram-scale production mode and transparent pricing for teams seeking that scale of output within constrained budgets. The relevant comparison is whether a workflow can supply the required protein consistently at a price that supports the planned experiments.

CFPS does not universally replace cell-based expression, and proteins requiring authentic glycosylation or complex post-translational modifications may still need eukaryotic hosts for biologically meaningful output. Investment should go where the platform’s strengths match the stage’s exposure. Faster screening protects discovery opportunity, interpretable comparisons protect optimization decisions, and dependable production protects preclinical work already committed. Expression infrastructure earns its place in the budget through the losses it helps prevent.